NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three... Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action".
- Mechanism
- Curator reviewed
NS2359 has a triple mode of action, inhibiting neuronal reuptake of the three neurotransmitters serotonin, noradrenaline and dopamine, all of which play an important role in the development of depression. NS2359 also increases release of the neurotransmitter acetylcholine. This mode of action is expected to produce a better and faster reduction of the symptoms associated with depression. This rationale has been confirmed in independent studies in which existing anti-depressants affecting serotonin have been combined with drugs that affect noradrenaline/dopamine. Drugs with this triple mode of action are expected to become the future standard in the treatment of depression.
- Primary indication
- Investigated for use/treatment in addictions, attention deficit/hyperactivity disorder (ADHD), and depression.Curator reviewed
- Formula / weight
- C16H21Cl2NO · 314.25 g/mol (avg)
- Code names
- GSK-372,475 · NS-2359
Resolves to
PGYDXVBZYKQYCS-VPWBDBDCSA-NSMILESCOC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C1=CC(Cl)=C(Cl)C=C1)N2CWhat you can answer from here — as of January 29, 2025
Which drugs share a target with NS-2359, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account